Related by context. All words. (Click for frequent words.) 77 Reports Positive 74 Announces Positive 74 Significant Increase 73 Receives Positive 70 Announces Publication 70 Progresses 70 Shows Promise 70 Completes Enrollment 70 Clinical Trial Results 70 Receives Approval 70 Preclinical Data 69 Receives Milestone Payment 69 Presents Positive 69 Announces Commencement 69 Exercises Option 68 Study Confirms 68 Signs Option Agreement 68 Announces Initiation 68 Provides Update 68 Results Confirm 68 Gets Boost 68 Present Preclinical Data 67 Announces Successful Completion 67 Announces Successful 67 Drug Candidate 67 Provides Updates 67 Net Loss Narrows 67 Phase 2b Clinical Trial 67 Updates Status 67 Presents Preclinical Data 67 Survival Benefit 67 Completes Patient Enrollment 67 Announces Presentation 67 Commences 67 Significantly Increases 66 More Than Doubles 66 Gets Approval 66 Updates Shareholders 66 Net Loss Widens 66 Moves Forward 66 Improves Survival 66 Receives Orphan Drug Designation 66 Successfully Completes 66 Significantly Improves 66 Additional Assay Results 66 Announces Termination 66 Study Indicates 66 Improves Outcomes 66 Better Than Expected 66 Successfully Completed 65 Remains Strong 65 Inter Citic Releases 65 Preliminary Results 65 Patients Treated 65 Completes Initial 65 Drilling Underway 65 Announces Preliminary 65 Study Showed 65 Provides Update Regarding 65 Phase III Trial 65 Drill Results 65 Phase IIb Trial 65 Underway 65 Announces Completion 65 Disappoints 65 Commences Phase 65 Seeks Approval 65 Report Indicates 65 FDA Clears 65 Increased Risk 65 Increases Risk 65 Study Demonstrates 65 Successful Completion 65 Shows Promising 65 Antitumor Activity 65 Finalizes Agreement 65 Significant Improvement 65 Completes Successful 65 Announcement Regarding 65 Summarizes 65 Lupus Drug 65 Up Sharply 65 Outperforms 65 Demonstrates Positive 65 Statistically Significant 65 Receives Conditional Approval 65 Receives Notice 64 Provides Guidance 64 Near Surface 64 Enters Into Agreement 64 Closes Sale 64 Gold Intercepts 64 Nears Completion 64 Results Indicate 64 Wraps Up 64 Discontinues 64 Record Highs 64 Confirms 64 Patients Suffering 64 Announce Completion 64 Univest Corporation Declares 64 Renegotiates 64 Be Discussed 64 Meets Primary Endpoint 64 Sees Strong 64 Plummets 64 Drilling Intersects 64 Ramps Up 64 Provides Operational Update 64 Earnings Rise 64 Well Tolerated 64 Re Affirms 64 Patient Enrollment 64 Significantly Reduces 64 Exceeds Expectations 64 Report Examines 64 Momentum Continues 64 Significantly Improved 64 Agreement Reached 64 Down Slightly 64 Announces Filing 64 Attains 64 Initiates Phase 64 Final Stages 64 Posts Strong 64 Long Awaited 64 Reaches Agreement 64 Improved Survival 64 Profitable Quarter 64 Modest Gains 64 Receives FDA Clearance 64 Submits 64 Begins Drilling 63 Mobilizes 63 Earnings Decline 63 Shareholders Approve Merger 63 Gets Underway 63 Be Studied 63 Initiates 63 Study Shows 63 Previously Treated 63 Previously Announced 63 Holds Steady 63 Anti Tumor Activity 63 Signs Agreement 63 FDA Approves 63 Initiates Phase II 63 News Unternehmensnachrichten 63 Closes Acquisition 63 Announce Collaboration 63 Discloses 63 Moves Ahead 63 Accelerates 63 Bodes Well 63 Sustains 63 Sees Positive 63 Up Slightly 63 Reaffirms Commitment 63 Launches Website 63 Proves Successful 63 Completes Purchase 63 Appears Safe 63 Submits Application 63 Issues Guidance 63 Identifies Potential 63 Much Needed 63 Draws Attention 63 FDA Okays 63 Drug Fails 63 Reduces Risk 63 Secures Funding 63 Successfully Treated 63 Trenching Results 63 Conjunction With 63 Demonstrates Significant 63 Provides Clarification 63 Receives Notification 63 Data Suggest 63 Achieves Milestone 63 Phase IIb Clinical Trial 63 Reconfirms 63 Study Evaluating 63 Obtains Approval 63 Enters Agreement 63 Confirms Significant 63 Loses Ground 63 Receives Order 63 Largest Ever 63 Slightly Higher 63 Being Tested 63 Obtains 63 Takes Steps 63 Announces Expanded 63 Announces Assay Results 63 Persists 63 Correlation Between 63 Wins Approval 63 Secures Financing 63 Upside Potential 63 Posts Wider Loss 63 Enter Into 63 Slightly Lower 63 Ramping Up 63 Plunges 63 Commence Drilling 63 Soars 62 Updates Guidance 62 Announces Availability 62 Gains Momentum 62 Announces Expansion 62 Higher Than Expected 62 Double Digit Growth 62 Intensifies 62 Anticipates 62 Commences Drilling 62 Phase 2a Trial 62 Worsens 62 Prolongs 62 Announces Resignation 62 Maintains Strong 62 Impresses 62 Achieves Positive 62 Receives Favorable 62 Quadruples 62 Launches Innovative 62 Strikes Deal 62 Remain Strong 62 Reach Agreement 62 Study Proves 62 Sets Record 62 Statement Regarding 62 Provides Detailed 62 Being Studied 62 Makes Strides 62 Optimistic About 62 Announces Intention 62 More Than Doubled 62 Signs Definitive Agreement 62 Announces Receipt 62 Raises Funds 62 Signs LOI 62 Completes Sale 62 Complete Merger 62 Bounces Back 62 Gears Up 62 Finalizes 62 Assay Results From 62 Wins Contract 62 Report Suggests 62 Pivotal Trials 62 Raise Awareness About 62 Validates 62 Lower Than Expected 62 Clinical Trial Evaluating 62 Significantly Expands 62 Posts Loss 62 Spectrum Pharmaceuticals Announces 62 Announces Signing 62 Signs Agreements 62 Is Well Tolerated 62 Provides Preliminary 62 Discovers 62 Announces Formation 62 Releases Findings 62 Ink Deal 62 Closes Financing 62 Cautious Optimism 62 Highlights Importance 62 Cites Positive 62 FDA Approvals 62 Drill Hole Results 62 Proudly Announces 62 Completes 62 Concerns Remain 62 Life Threatening 62 Announce Partnership 62 Will Remain 62 Provides Updated 62 Announces Discontinuation 62 Pivotal Phase III 62 Significant Reduction 62 Few Surprises 62 Study Suggests 62 Nine Month 62 Announces Revised 62 Temporarily Suspends 62 Receives Conditional 62 Posts Profit 62 Advanced Melanoma 62 Completes Merger 62 Announces 62 Lowest Level 62 Blood Clots 62 Completes Drilling 62 Huge Success 62 Sharply Higher 62 Gains Ground 61 Announces Proposed 61 Sees Increase 61 Shareholders Approve 61 Signs Contract 61 Effective Than 61 Could Trigger 61 Forges Ahead 61 Regains 61 Expands 61 Combination Treatment 61 Announces Closing 61 Arthritis Drug 61 Significantly Reduce 61 Opens Doors 61 Moves Towards 61 Terminates 61 Posts Record 61 Being Evaluated 61 Move Into 61 Shares Soar 61 Annouces 61 Warning Issued 61 Deepens 61 Pursues 61 Changes Name 61 Retracts 61 Important Milestone 61 Generates Record 61 Patients Treated With 61 Commences Exploration 61 Receives Prestigious Award 61 Executes Agreement 61 Expansion Plans 61 Announces Acquisition 61 Diversifies 61 Strengthens Balance Sheet 61 Little Changed 61 Preclinical Study 61 Intersects 61 Jointly Develop 61 Infill Drilling Program 61 Jumps Higher 61 Helps Identify 61 Sees Higher 61 Receives Patent 61 Slight Improvement 61 Gets Nod 61 Could Harm 61 Announces FDA Clearance 61 Extends Offer 61 Succeeds 61 Be Tested 61 Moves Into 61 Receives Positive Results 61 Completes Transaction 61 Announce Agreement 61 Recommences 61 Achieves Record 61 Reveals Secrets 61 Announces Departure 61 Q3 Loss Narrows 61 Continues 61 Metallurgical Testing 61 Nearing Completion 61 Gets Thumbs Up 61 Loss Widens 61 Reinforces 61 Effectively Treats 61 Finalises 61 Rises Sharply 61 Signs MOU 61 Shareholder Opinions 61 Winding Down 61 Looks Ahead 61 Slows Down 61 Study Validates 61 NuMobile NUBL 61 Restricts Access 61 Shows Signs 61 Has Received 61 Strengthens Its 61 Pave Way 61 Scaled Back 61 Resumes Drilling 61 Prolongs Survival 61 Profits Rise 61 Completes Expansion 61 Move Toward 61 Enters Into 61 Amends Agreement 61 Breast Cancer Patients 61 Raises Concerns 61 Achieves Record Sales 61 Significant Improvements 61 Announces Launch 61 Key Milestones 61 Protease Inhibitor 61 Announces Upcoming 61 Down Sharply 61 Completes Financing 61 Elevates 61 Consummates 61 Extends Contract 61 Evolves 61 Could Become 61 Acquire Controlling Interest 61 Q2 Loss Widens 61 Holds Promise 61 JAK Inhibitor 61 Commercialize 61 Relapsing Multiple Sclerosis 61 Increases Ownership 61 Significantly Expand 61 Sign Licensing Agreement 61 High Grade Intercepts 61 Signs Letter 61 Announces Cancellation 61 Epilepsy Drug 61 Receives Regulatory 61 Silver Mineralization 61 Outpaces 61 Announce Commencement 61 Substantial Increase 61 Expand Collaboration 61 Resigns 61 Drilling Extends 61 Swings To 61 Receives 61 Reacquires 61 Reaches Milestone 61 Amplifies 61 Adjunctive Therapy 61 Be Explored 61 Stays Strong 61 Commences Production 61 Study Examines 61 Slight Increase 61 Monetizes 61 Receives Confirmation 61 Drilling Continues 61 Jointly Announce 60 Announce Signing 60 Newly Diagnosed Multiple Myeloma 60 Pushes Back 60 Q3 Loss Widens 60 Antiviral Drugs 60 Carried Out 60 Restates 60 Initiates Drilling 60 Announces Addition 60 Makes Debut 60 Announces Licensing Agreement 60 Announces Intent 60 Q4 Loss Narrows 60 Study Sheds Light 60 Paves Way 60 Abandons 60 Q4 Loss Widens 60 Flamel Technologies Announces 60 Posts Higher 60 Widens 60 Announce Settlement 60 Completes Private Placement 60 Mixed Reviews 60 Shares Surge 60 Investigational Drug 60 Negotiations Continue 60 Expands Coverage 60 Proven Effective 60 Board Authorizes 60 First Patient Enrolled 60 Engages 60 Refocuses 60 Loss Narrows 60 Beneficial Effects 60 Postpones 60 Provides Shareholder 60 Delineates 60 Initiates Clinical Trials 60 Ruled Out 60 Completes Acquisition 60 Announces Non Brokered 60 Momentum Builds 60 Osteoporosis Drug 60 Receives Recognition 60 FDA Warns 60 Beefs Up 60 Kicks Off 60 Withdraws 60 Files Patent Application 60 Bolsters 60 Drill Intercepts 60 Trial Halted 60 Restructures 60 Study Identifies 60 Edges Up 60 Be Evaluated 60 Multiple Myeloma Patients 60 Reports Profitable 60 Revenues Increase 60 Website Launched 60 Revolutionizes 60 Sangamo BioSciences Announces 60 Breaks Out 60 Mixed Reactions 60 Attracts 60 Highest Ever 60 Adjourns 60 Newly Acquired 60 Rise Sharply 60 Closes Previously Announced 60 Helps Reduce 60 Acquire Assets 60 Proves Effective 60 Increases Quick Facts 60 Approve Merger 60 Dominates 60 Panel Backs 60 Reactivates 60 Closes Private Placement 60 Moves Closer 60 Extends Losses 60 Demonstrates Ability 60 Significantly Reduced 60 Significantly Improve 60 Announce Collaboration Agreement 60 Underpin 60 Sales Soar 60 Has Commenced 60 Signs Deal 60 Q1 Loss Widens 60 Guidance Quick Facts 60 Drilling Confirms 60 Grants Options 60 Stem Cell Treatment 60 Milestone Achieved 60 Bush Embraces Pause 60 Reaps 60 Largely Unchanged 60 Remains Positive 60 Shows Efficacy 60 Expand Relationship 60 Surface Sampling 60 Develop Novel 60 Drilling Completed 60 Single Dose 60 TriCo Bancshares Announces 60 Well Positioned 60 Terminates Contract 60 Announces Retirement 60 Refines 60 Looks Promising 60 Issues Statement Regarding 60 Acquires Assets 60 Heats Up 60 Highly Anticipated 60 Pulls Out 60 Prostate Cancer Vaccine 60 Double Digit 60 Lung Cancer Drug 60 Long Term Survival 60 Gold Mineralization 60 Tempers Flare 60 Outshines 60 Gets Ready 60 Distinguishes 60 Relaunches 60 Stronger Than Ever 60 Announces Postponement 60 Heading Into 60 Sees Continued 60 Raises Awareness 60 Attracts Attention 60 Picks Up 60 Raises Concern 60 Falters 60 Announces Sponsorship 60 Osteoporosis Treatment 60 Latest Addition 60 Sign License Agreement 60 Controlled Trial 60 Plays Role 60 Issues Clarification 60 Posts Lower 60 Fall Sharply 60 Lowers Risk 60 Concludes Successful 60 Sign Pact 60 Talks Continue 60 Opts 60 Successfully Completes Phase 60 Inhibits 60 Undertakes 60 Help Prevent 60 Faces Lawsuit 60 HCV Protease Inhibitor 60 Projected Release Date 60 Viable Option 60 Drug Resistant 60 Delivers Strong 60 Recieves 60 Causes Concern 60 Pinnacle Digest Looking 60 Shed Light 60 Statin Therapy 60 Drilling Commences 60 Treatment Reduces 60 Insights Into 60 Could Prove 60 Focus Shifts 60 Reaffirms 60 Thrives 60 Improve Survival 60 NDA Submission 60 Oral Fingolimod 60 Shares Plummet 60 Celebrates Successful 60 Gaining Traction 60 Inks Deal 60 Settlement Reached 60 Beat Estimates 60 Reduces Debt 60 IrelandRESEARCH AND MARKETS 60 Profits Soar 60 Insight Into 60 Issues Statement 60 Teaming Up 60 Report Identifies 60 Backs Away 60 Energizes 60 Reach Settlement 60 Rheumatoid Arthritis Patients 60 Clinical Efficacy 60 Confirms Receipt 60 Shares Tumble 60 Publishes 60 Elicits 60 Files NI #-# 60 Outlines Plans 60 Seek Help 60 VIVUS Announces 60 Gaining Momentum 60 Concerns Raised 60 Potentially Fatal 60 Emerges 60 Contract Dispute 60 Rejoins 60 Cuts Costs 60 Confirms Efficacy 60 Breast Cancer Treatment 60 Below Estimates 60 PPD Declares 60 Step Closer 60 Remains Steady 60 Elderly Patients 60 Affirms Commitment 60 Revenues Decline 60 Drug Coated Stents 60 Announces Dates 60 Sustained Efficacy 60 Entices 59 Heightens 59 Awarded Contract 59 Cholesterol Drug 59 Receives Commitment 59 Announce Receipt 59 Draws Crowds 59 Subsidiary Acquires 59 Above Consensus 59 Expands Scope 59 Drop Sharply 59 Signs Pact 59 Profit Surges 59 Receives Certification 59 Announces Issuance 59 Reveals 59 Panel Rejects 59 Phase 2b Study 59 Recommends Approval 59 Gout Drug 59 Signs Memorandum 59 Reschedules 59 Makes Waves 59 Milestone Reached 59 StockSource.us Reports 59 Sees Surge 59 Pediatric Patients 59 Identifies Significant 59 Announces Divestiture 59 Copper Mineralization 59 Expects Higher 59 Successfully Concludes 59 Than Expected 59 Acquires 59 Remain Steady 59 Demonstrated Significant 59 1Q Loss 59 Heading Towards 59 Announces License Agreement 59 Signs Long Term 59 Being Treated 59 1st Quarter Results 59 Long Term Efficacy 59 Repays 59 Combination Therapy 59 Study Finds 59 Clears Path 59 Robust Growth 59 Increases Stake 59 Viral Suppression 59 La Mina Porphyry 59 Patients Receiving 59 Identifies Key 59 Finalizes Sale Of 59 Less Likely 59 Successfully Complete 59 Versus Placebo 59 Proves 59 Steps Toward 59 Remains Flat 59 Resolve Dispute 59 Satisfies 59 Assay Results 59 Funds Announce 59 Receives Favorable Ruling 59 Safer Than 59 Postmenopausal Women 59 Cancer Cells 59 Achieves Significant 59 Shares Climb 59 Orally Active 59 Reaches Settlement 59 Reach Deal 59 Readies 59 Announces Private Placement 59 Ceases 59 Anti Tumor 59 Q2 Loss Narrows 59 Therapeutic Potential 59 Lined Up 59 Completes Sale Of 59 Announces Favorable 59 Settles Litigation 59 Stronger Than Expected 59 Be Treated 59 Continues Momentum 59 Metres Grading 59 Collaborators Publish 59 Provides Insights 59 Enhances 59 Sustained Reduction 59 Makes Headway 59 Foreshadows 59 Announce License Agreement 59 Reclassifies 59 Investors Await 59 Demonstrates Improved 59 Raise Questions 59 Fortifies 59 Unveils Latest 59 Backs Off 59 Explore Strategic Alternatives 59 Expansion Continues 59 Pending Acquisition 59 Releases Third Quarter 59 Study Links 59 Announces Webcast 59 Announces Affiliation 59 Record Third Quarter 59 Relocates 59 Adverse Effects 59 Has Entered 59 Steps Up 59 Alert Issued 59 Stepping Down 59 Reduce Risk 59 Weak Dollar 59 Report Finds 59 Radical Prostatectomy 59 Migraine Drug 59 Achieves Highest 59 Opens Door 59 Awaits Approval 59 Enters Final 59 Pays Off 59 Nears End 59 Filed Against 59 Posts Narrower Loss 59 Diabetic Patients 59 Brain Atrophy 59 Overwhelming Support 59 Percent Jump 59 Shares Plunge 59 Commends 59 Takes Stand 59 Versus Majors 59 Gene Mutation 59 Combination REOLYSIN R 59 Questions Arise 59 View Quick Facts 59 Preclinical Models 59 Bone Metastases 59 Blood Thinner 59 4Q Loss 59 Halts Production 59 Multi Billion Dollar 59 Investigational Agent 59 Enters Into Letter 59 Fends Off 59 Extends Mineralization 59 Anounces 59 Remains Optimistic 59 Taking Shape 59 Pushed Back 59 Third Consecutive 59 Announce Initiation 59 Boosts 59 Halts 59 Cervical Cancer Vaccine 59 Enters Joint Venture 59 Shown Effective 59 Gain Traction 59 Negotiates 59 Worsen 59 Delayed Again 59 Prices Drop 59 Furthers 59 Deal Reached 59 Underscore Need 59 Goes Live 59 Entry Into 59 Demonstrates 59 Milestone Payment 59 Futures Rise 59 Dramatically Increases 59 Guidelines Issued 59 Expansion Into 59 Bulks Up 59 Slow Start 59 4Q Loss Narrows 59 Dramatic Increase 59 Beats Expectations 59 Closes Acquisition Of 59 Rheumatoid Arthritis Drug 59 Caution Urged 59 Starts Drilling 59 Improve Efficiency 59 Subsidiary Signs 59 CORRECTION FROM SOURCE 59 Extends Reach 59 Announces Resumption 59 Kidney Transplants 59 Posts Solid 59 Stands Out 59 Expands Reach 59 Remain Positive 59 Be Unveiled 59 Looks Toward 59 2nd Quarter Results 59 Sequential Increase 59 Announces Granting 59 Helps Boost 59 Receives Unsolicited 59 Cholesterol Lowering Drug 59 Continues Expansion 59 Slow Progression 59 Gains Traction 59 Randomized Trials 59 Could Endanger 59 Draw Attention 59 Brings Together 59 Receives Permit 59 Decision Delayed 59 Grows 59 Enters Into Definitive Agreement 59 Demonstrates Potential 59 Pooled Analysis 59 Targets Identified 59 Wrapping Up 59 Adjuvant Therapy 59 Remain Unchanged 59 Consolidates 59 Launches 59 Crowflight Announces 59 Transdermal Patch 59 Tight Lipped 59 Expands Presence 59 Lawsuits Filed 59 Commences Operations 59 Sharply Lower 59 Extends Deadline 59 FFO Rises 59 Rate Climbs 59 Drops Sharply 59 Below Consensus 59 Makes Comeback 59 Leveling Off 59 Meta Analysis 59 Treatment Naive Patients 59 Losses Narrow 59 Weaker Than Expected 59 Offers Unique 59 Fifth Consecutive 59 File Suit 59 Receives Prestigious 59 Evidence Suggests 59 Refuses To 59 Further Strengthens 59 Be Released 59 Be Removed 59 Drug Shows Promise 59 Monotherapy 59 Secures Additional 58 Debuts 58 Concludes 58 Closes Second Tranche 58 Revises Guidance 58 Remains Committed 58 Urge Caution 58 Smallpox Vaccine 58 Cautiously Optimistic About 58 Sees Rise 58 Fourth Consecutive 58 Signs Definitive Agreements 58 Upcoming Conferences 58 Trial Begins 58 Being Investigated 58 Be Showcased 58 Lose Ground 58 REPLACING 58 Enters Into Agreements 58 Record Setting 58 Raises Guidance 58 Step Toward 58 Therapeutic Antibody 58 Trend Continues 58 Demonstrates Commitment 58 Warned About 58 Enters Into Joint Venture 58 Forms Joint Venture 58 Renews Contract 58 Options Activity 58 Wanes 58 Near Term 58 Positions Itself 58 Reports Significantly Improved 58 Signs Licensing Agreement 58 Host Webcast 58 Awarded Patent 58 Solidifies 58 Expand Into 58 Results Exceed Expectations 58 Secures 58 Second Consecutive 58 Gives Boost 58 Commences Drill Program 58 Eighth Consecutive 58 Drilling Update 58 Reports Assay Results 58 Q1 Loss Narrows 58 Stocks Mixed 58 Urgently Needed 58 Study Reinforces 58 Acquires Controlling Interest 58 Virtually Unchanged 58 Infected Patients 58 Stimulates 58 Grants Awarded 58 Stirs Controversy 58 Picked Up 58 Debate Continues 58 Relapsed Multiple Myeloma 58 Enters Into Negotiations 58 Signs License Agreement 58 Advanced Prostate Cancer 58 Promotes 58 Rotavirus Vaccine 58 Sees Decline 58 Helps Prevent 58 Suspends 58 Economic Woes 58 Strongly Linked 58 Seeks Answers 58 Ranks Highest 58 Wide Ranging 58 Latest Developments 58 Remain Flat 58 Underlie 58 Hits Record 58 Study Shows Benefits 58 Outlines Strategy 58 Gaining Steam 58 Under Scrutiny 58 Make Headway 58 Bare Metal Stents 58 Resurfaces 58 Apfn 58 Q2 Profit Rises 58 Announce Merger Agreement 58 Update6 58 Report Reveals 58 Costs Rise